EP
FATE icon

Eversept Partners’s Fate Therapeutics FATE Stock Holding History

Eversept Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-43,562
Closed -$440K – 68
2022
Q4 		$440K Sell
43,562
-97,996
-69% -$1.84M 0.04% 60
2022
Q3 		$3.17M Sell
141,558
-585,028
-81% -$16.9M 0.28% 44
2022
Q2 		$18M Buy
726,586
+270,527
+59% +$7.46M 1.28% 24
2022
Q1 		$17.7M Buy
456,059
+201,269
+79% +$7.79M 1.36% 23
2021
Q4 		$14.9M Sell
254,790
-6,105
-2% -$346K 0.95% 30
2021
Q3 		$15.5M Sell
260,895
-85,452
-25% -$6.7M 1.07% 27
2021
Q2 		$30.1M Buy
346,347
+24,587
+8% +$1.98M 2% 19
2021
Q1 		$26.5M Sell
321,760
-77,739
-19% -$7.45M 1.37% 22
2020
Q4 		$36.3M Sell
399,499
-135,537
-25% -$8.42M 4.26% 7
2020
Q3 		$21.4M Buy
535,036
+3,778
+0.7% +$132K 4.75% 7
2020
Q2 		$18.2M Buy
531,258
+225,773
+74% +$6.73M 2.5% 14
2020
Q1 		$6.78M Sell
305,485
-55,171
-15% -$1.4M 1.69% 17
2019
Q4 		$7.06M Buy
360,656
+220,000
+156% +$3.49M 1.25% 22
2019
Q3 		$2.18M Sell
140,656
-77,200
-35% -$1.48M 0.68% 32
2019
Q2 		$4.42M Sell
217,856
-132,155
-38% -$2.38M 1.24% 22
2019
Q1 		$6.15M Buy
350,011
+185,011
+112% +$2.92M 1.79% 15
2018
Q4 		$2.12M Buy
+165,000
New +$2.3M 1.15% 20

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Eversept Partners's FATE Position: Q1 2023 in Review

Eversept Partners sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 43,562 shares — an estimated $440K sold.

Eversept Partners first reported a position in FATE in Q4 2018 and held it in 17 quarters. The position peaked at $36.3M in Q4 2020. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Eversept Partners reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Eversept Partners sold 43,562 Fate Therapeutics shares in Q1 2023, an estimated $440K.
  • Eversept Partners first reported a position in Fate Therapeutics in Q4 2018 and held it in 17 quarters.
  • Eversept Partners's Fate Therapeutics position peaked at $36.3M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Eversept Partners's 13F filing for Q1 2023, filed 15 May 2023.